Lidocaine‐induced potentiation of thermal damage in skin and carcinoma cells. Issue 1 (15th October 2018)

• Record Type: Journal Article
• Authors: Raff, Adam B.; Thomas, Carina N.; Chuang, Gary S.; Avram, Mathew M.; Le, Monica H.; Anderson, R. Rox; Purschke, Martin
• Other Names: Kelly Kristen M. guestEditor.; DiGiorgio Catherine M. guestEditor.; Ortiz Arisa E. guestEditor.
• Is Part Of: Lasers in surgery and medicine. Volume 51:Issue 1(2019)
• Page Start: 88
• Page End: 94
• Publication Date: 2018-10-15
• Subjects: hyperthermia -- heat -- moderate temperatures -- local anaesthetics -- lidocaine -- cancer treatment -- skin cell lines; Lasers in medicine -- Periodicals; Lasers in surgery -- Periodicals; 617
• DOI: 10.1002/lsm.23027
• Languages: English
• ISSNs: 0196-8092

Abstract

Abstract : Objective: Lidocaine acts as a local anesthetic by blocking transmembrane sodium channel permeability, but also induces the synthesis of heat shock proteins and sensitizes cells to hyperthermia. A previous study reported two cases of deep focal skin ulceration at points corresponding to depot local lidocaine injection sites after treatment with non‐ablative fractional resurfacing and it was hypothesized that lidocaine had focally sensitized keratinocytes to the thermal damage of laser treatment. The objective of this study was to investigate whether lidocaine potentiates hyperthermia damage to both normal and cancerous skin cells using an in vitro model. Methods: Normal skin cell lines (fibroblasts, keratinocytes), skin cancer cell lines (melanoma, basal cell carcinoma), and a mucosal cancer cell line (cervical carcinoma) were exposed to various concentrations of lidocaine (0–0.3%) with or without hyperthermia (37°C, 42°C). Results: Compared to normal skin cells, we demonstrate that cancer cell lines show significantly increased cell toxicity when a moderate temperature (42°C) and low lidocaine concentrations (0.1–0.2%) are combined. The toxicity directly correlates with a higher percentage of cells in S‐phase (28–57%) in the cancer cell lines compared to normal skin cell lines (13–19%; R‐square 0.6752). Conclusion: These results suggest that lidocaine potentiates thermal sensitivity of cell cycle active skin cells. The direct correlation between cell toxicity and S‐phase cells could be harnessed to selectively treat skin and mucosal cancer cells while sparing the surrounding normal tissue. Additional research pre‐clinically and clinically using several different heat sources (e.g., lasers, ultrasound, etc.) and lidocaine concentrations is needed to confirm and optimize these results. Lidocaine‐enhanced hyperthermia may provide a non‐invasive, alterative treatment option for highly proliferating, superficial skin, and mucosal lesions such as cancer or warts. Lasers Surg. Med. 51:88–94, 2019. © 2018 Wiley Periodicals, Inc.